Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

555 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Polyethylenimines for RNAi-mediated gene targeting in vivo and siRNA delivery to the lung.
Günther M, Lipka J, Malek A, Gutsch D, Kreyling W, Aigner A. Günther M, et al. Eur J Pharm Biopharm. 2011 Apr;77(3):438-49. doi: 10.1016/j.ejpb.2010.11.007. Epub 2010 Nov 18. Eur J Pharm Biopharm. 2011. PMID: 21093588 Review.
RNA interference (RNAi) is a promising strategy to inhibit the expression of pathologically relevant genes, which show aberrant (over-)expression, e.g. in tumors or other pathologies. ...This review article gives a comprehensive overview of pre-clinical in vivo stud …
RNA interference (RNAi) is a promising strategy to inhibit the expression of pathologically relevant genes, which show aberrant (over …
In vivo pharmacokinetics, tissue distribution and underlying mechanisms of various PEI(-PEG)/siRNA complexes.
Malek A, Merkel O, Fink L, Czubayko F, Kissel T, Aigner A. Malek A, et al. Toxicol Appl Pharmacol. 2009 Apr 1;236(1):97-108. doi: 10.1016/j.taap.2009.01.014. Epub 2009 Jan 29. Toxicol Appl Pharmacol. 2009. PMID: 19371615
BACKGROUND: RNA interference (RNAi) represents a novel therapeutic strategy allowing the knockdown of any pathologically relevant target gene. ...PURPOSE: The present study determines in vivo pharmacokinetics, tissue distribution/efficacy of siRNA delivery and adverse effe …
BACKGROUND: RNA interference (RNAi) represents a novel therapeutic strategy allowing the knockdown of any pathologically relevant tar …
HMGA2 gene is a promising target for ovarian cancer silencing therapy.
Malek A, Bakhidze E, Noske A, Sers C, Aigner A, Schäfer R, Tchernitsa O. Malek A, et al. Int J Cancer. 2008 Jul 15;123(2):348-356. doi: 10.1002/ijc.23491. Int J Cancer. 2008. PMID: 18452175
This gene codes the HMGA2 protein, a member of the high-mobility group AT-hook (HMGA) family of nonhistone chromatin proteins. ...Our findings revealed that the HMGA2 gene represents a promising target for gene silencing therapy in ovarian cancer....
This gene codes the HMGA2 protein, a member of the high-mobility group AT-hook (HMGA) family of nonhistone chromatin proteins. ...Our …
PEG grafting of polyethylenimine (PEI) exerts different effects on DNA transfection and siRNA-induced gene targeting efficacy.
Malek A, Czubayko F, Aigner A. Malek A, et al. J Drug Target. 2008 Feb;16(2):124-39. doi: 10.1080/10611860701849058. J Drug Target. 2008. PMID: 18274933
A more detailed analysis reveals that, in order to define optimal N/P ratios for DNA transfection, complex toxicities and nucleic acid uptake are the most critical parameters. ...CONCLUSION: In contrast to PEI(-PEG)/DNA complexes, a broader panel of PEI-PEG are capa
A more detailed analysis reveals that, in order to define optimal N/P ratios for DNA transfection, complex toxicities and nucleic aci
Polyethylenimine PEI F25-LMW allows the long-term storage of frozen complexes as fully active reagents in siRNA-mediated gene targeting and DNA delivery.
Höbel S, Prinz R, Malek A, Urban-Klein B, Sitterberg J, Bakowsky U, Czubayko F, Aigner A. Höbel S, et al. Eur J Pharm Biopharm. 2008 Sep;70(1):29-41. doi: 10.1016/j.ejpb.2008.03.014. Epub 2008 Mar 30. Eur J Pharm Biopharm. 2008. PMID: 18499413
Since RNAi represents a powerful method for specific gene silencing, the PEI-based delivery of siRNAs is a promising tool for novel putative therapeutic strategies. ...In this paper, we explore the potential of PEI F25-LMW, a low-molecular weight PEI with sup …
Since RNAi represents a powerful method for specific gene silencing, the PEI-based delivery of siRNAs is a promising tool for …
PAMAM dendrimers for siRNA delivery: computational and experimental insights.
Pavan GM, Posocco P, Tagliabue A, Maly M, Malek A, Danani A, Ragg E, Catapano CV, Pricl S. Pavan GM, et al. Chemistry. 2010 Jul 12;16(26):7781-95. doi: 10.1002/chem.200903258. Chemistry. 2010. PMID: 20496352
Short double-stranded RNAs, which are known as short interfering RNA (siRNA), can be used to specifically down-regulate the expression of the targeted gene in a process known as RNA interference (RNAi). ...The dendrimers and their siRNA complexes were structurally characte …
Short double-stranded RNAs, which are known as short interfering RNA (siRNA), can be used to specifically down-regulate the expression of th …
RNAi-mediated silencing of Myc transcription inhibits stem-like cell maintenance and tumorigenicity in prostate cancer.
Civenni G, Malek A, Albino D, Garcia-Escudero R, Napoli S, Di Marco S, Pinton S, Sarti M, Carbone GM, Catapano CV. Civenni G, et al. Cancer Res. 2013 Nov 15;73(22):6816-27. doi: 10.1158/0008-5472.CAN-13-0615. Epub 2013 Sep 24. Cancer Res. 2013. PMID: 24063893
Myc is a transcription factor having a central function in stem cell biology and in human cancers. Hence, Myc represents an attractive target to develop CSC-specific therapies. ...Notably, systemic delivery of the promoter-targeting siRNA in the xenograft model prod …
Myc is a transcription factor having a central function in stem cell biology and in human cancers. Hence, Myc represents an at …
Evaluation of targets for ovarian cancer gene silencing therapy: in vitro and in vivo approaches.
Malek A, Tchernitsa O. Malek A, et al. Methods Mol Biol. 2010;623:423-36. doi: 10.1007/978-1-60761-588-0_27. Methods Mol Biol. 2010. PMID: 20217567
Gene silencing therapy represents a possible opportunity to advance the management of ovarian cancer patients. The concept of gene silencing therapy, which is based on RNA interference (RNAi) phenomenon, requires selection of targeted genes and development of a stra …
Gene silencing therapy represents a possible opportunity to advance the management of ovarian cancer patients. The concept of gene si …
Modulation of the activity of Sp transcription factors by mithramycin analogues as a new strategy for treatment of metastatic prostate cancer.
Malek A, Núñez LE, Magistri M, Brambilla L, Jovic S, Carbone GM, Morís F, Catapano CV. Malek A, et al. PLoS One. 2012;7(4):e35130. doi: 10.1371/journal.pone.0035130. Epub 2012 Apr 19. PLoS One. 2012. PMID: 22545098 Free PMC article.
Mithramycin A (MTM-A) is a natural polyketide that binds GC-rich DNA sequences, inhibits activity of Sp TFs and exhibits potent antitumor activity in experimental systems. However, clinical use of MTM-A is limited by the severe toxicity of the compound …
Mithramycin A (MTM-A) is a natural polyketide that binds GC-rich DNA sequences, inhibits activity of Sp TFs and exhibit …
A sensitive polymerase chain reaction-based method for detection and quantification of metastasis in human xenograft mouse models.
Malek A, Catapano CV, Czubayko F, Aigner A. Malek A, et al. Clin Exp Metastasis. 2010 Apr;27(4):261-71. doi: 10.1007/s10585-010-9324-1. Epub 2010 Apr 4. Clin Exp Metastasis. 2010. PMID: 20364399
We have developed a quantitative real-time PCR-based assay for the detection and quantification of human tumor cells disseminated in mouse organs. ...We describe a very sensitive assay for the highly reproducible detection and accurate quantification of human metast …
We have developed a quantitative real-time PCR-based assay for the detection and quantification of human tumor cells disseminated in …
555 results
Jump to page
Feedback